Drug firm Cadila Healthcare on Friday said its manufacturing plant at Ankleshwar in Gujarat has completed inspection by the US health regulator with no observations.
The United States Food and Drug Administration (USFDA) inspected the company's active pharmaceutical ingredient manufacturing facility located at Ankleshwar from July 22-26, 2019, Cadila Healthcare said in a filing to BSE.
This audit covered both Unit I and II. At the end of the inspection, no 483 observations were issued, it added.
Shares of Cadila Healthcare settled at Rs 234.05 per scrip on BSE, up 1.76 per cent from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
